{"id":"NCT03222583","sponsor":"AbbVie","briefTitle":"A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-04","primaryCompletion":"2018-10-18","completion":"2019-02-15","firstPosted":"2017-07-19","resultsPosted":"2019-12-23","lastUpdate":"2019-12-23"},"enrollment":546,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus (HCV)"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Glecaprevir/Pibrentasvir","otherNames":["ABT-493/ABT-530","MAVYRET™"]}],"arms":[{"label":"Glecaprevir/Pibrentasvir","type":"EXPERIMENTAL"},{"label":"Placebo / Glecaprevir/Pibrentasvir","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in non-cirrhotic chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with or without human immunodeficiency virus (HIV) co-infection who are HCV treatment-naïve or treatment-experienced with interferon (IFN) with or without ribavirin (RBV), OR sofosbuvir with RBV with or without IFN.","primaryOutcome":{"measure":"Percentage of HCV GT1 - GT6-Infected Participants in Arm A Who Achieved Sustained Virologic Response 12 Weeks Post Treatment (SVR12)","timeFrame":"12 weeks after the last actual dose of study drug, Week 20 or Week 28 depending on the treatment regimen.","effectByArm":[{"arm":"Arm A: Glecaprevir/Pibrentasvir","deltaMin":97.2,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":48,"countries":["China","Singapore","South Korea"]},"refs":{"pmids":["32682494"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":362},"commonTop":["Upper respiratory tract infection"]}}